Open access
Open access
Powered by Google Translator Translator

Lipids

Podcast | Advanced lipidology.

30 Nov, 2022 | 13:32h | UTC

#361 Advanced Lipidology – The Curbsiders

 


RCT | Vitamin D fails to prevent statin-associated muscle symptoms among new statin users.

25 Nov, 2022 | 12:40h | UTC

Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo – JAMA Cardiology (free for a limited period)

Commentary: Vitamin D fails to reduce statin-associated muscle pain – Northwestern University

 

Commentary on Twitter

 


Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.

23 Nov, 2022 | 14:02h | UTC

Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease – Journal of the American College of Cardiology

Editorial: HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity? – Journal of the American College of Cardiology

News Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health

Commentary: Study suggests that HDL or ‘good’ cholesterol is less beneficial than previously thought, especially for Black adults – CNN

 


Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.

17 Nov, 2022 | 12:17h | UTC

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials – European Heart Journal

Commentary: Inclisiran and Cardiovascular Events – American College of Cardiology

 

Commentary on Twitter

https://twitter.com/ESC_Journals/status/1592113799481692162

 


RCT | Comparative effects of low-dose rosuvastatin vs. dietary supplements on lipids and inflammatory biomarkers.

16 Nov, 2022 | 13:41h | UTC

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers – Journal of the American College of Cardiology

News Release: 6 common “heart-health” supplements ineffective at lowering cholesterol compared to statins – American Heart Association

Commentaries: 

Study – For Lowering Cholesterol, Statins Work, Supplements Don’t – Science-Based Medicine

Statins vs. supplements: New study finds one is vastly superior to cut cholesterol NPR

 


Canadian guideline for the prevention and management of cardiovascular disease in primary care.

8 Nov, 2022 | 12:37h | UTC

Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update – Canadian Medical Association Journal

News Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal

 


Phase 2 RCT | Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease.

8 Nov, 2022 | 12:30h | UTC

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Clinical trial finds novel therapy markedly reduced lipoprotein(a) levels in people with cardiovascular disease – Brigham and Women’s Hospital

 

Commentary on Twitter

 


RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.

7 Nov, 2022 | 12:54h | UTC

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)

News Releases:

New medicine reduces triglyceride by 25%, no change in CVD risk in people with Type 2 diabetes – American Heart Association

Triglyceride-lowering trial neutral for cardiovascular event reduction – Brigham and Women’s Hospital

Commentaries:

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD

PROMINENT: Pemafibrate Effective in Lowering Tryglycerides, But Not Reducing Risk of CV Events – American College of Cardiology

 

Commentary on Twitter

 


Guidance for the diagnosis and treatment of hypolipidemia disorders.

28 Oct, 2022 | 13:19h | UTC

Guidance for the diagnosis and treatment of hypolipidemia disorders – Journal of Clinical Lipidology

 


Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.

20 Oct, 2022 | 12:25h | UTC

Associations of Hypertriglyceridemia Onset Age With Cardiovascular Disease and All‐Cause Mortality in Adults: A Cohort Study – Journal of the American Heart Association

 


Cross-sectional study | Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.

20 Oct, 2022 | 12:22h | UTC

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease – openheart

 

Commentary on Twitter

Under a http://creativecommons.org/licenses/by-nc/4.0/ license

 


RCT | Combination of pitavastatin and ezetimibe vs. monotherapy of pitavastatin in patients with primary hypercholesterolemia.

19 Oct, 2022 | 14:15h | UTC

A Multicenter, Randomized, Double-Blind, Active-Controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia – Clinical Therapeutics

 


Perspective | The polypill: from concept and evidence to implementation.

18 Oct, 2022 | 12:55h | UTC

The polypill: from concept and evidence to implementation – The Lancet (free registration required)

News Release: The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts – McMaster University

Related:

#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

#ESCCongress – M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention.

Opinion: A new important study supports wider use of the polypill

#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

Perspective: Are Polypills and Population-based Treatment the Next Big Things?

The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era

Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population

Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart

Perspective: The Polypill and the Long Journey to Major Impact

Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

 


Calculator | Estimating individual lifetime risk of cardiovascular events in adults with type 2 diabetes.

11 Oct, 2022 | 13:29h | UTC

Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2) – European Journal of Preventive Cardiology

See also: DIAL Model Calculator

 


Cohort Study | Association between dairy intake and risk of CV disease and mortality in patients with stable angina pectoris.

28 Sep, 2022 | 13:38h | UTC

The association between dairy intake and risk of cardiovascular disease and mortality in patients with stable angina pectoris – European Journal of Preventive Cardiology

 


Network M-A | Associations between statins and adverse events in secondary prevention of cardiovascular disease.

20 Sep, 2022 | 13:30h | UTC

Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials – Frontiers in Cardiovascular Medicine

 


Network M-A | Comparative efficacy of lipid‐lowering therapies added to maximally tolerated statins for the reduction of LDL cholesterol.

11 Sep, 2022 | 22:38h | UTC

Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol – Journal of the American Heart Association

 


2022 ACC Expert Consensus | Role of nonstatin therapies for LDL-cholesterol lowering and managing cardiovascular disease risk.

2 Sep, 2022 | 13:17h | UTC

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

News Release: ACC Issues Guidance to Address New Nonstatin Therapies – American College of Cardiology

Commentary: New on the Scene Nonstatin Drugs: Experts Provide Guidance – TCTMD

 

Commentary on Twitter

 


#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.

30 Aug, 2022 | 12:16h | UTC

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials – The Lancet

News Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology

Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD

 


#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.

30 Aug, 2022 | 12:12h | UTC

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease – Circulation

News Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology

Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine

 

Commentary on Twitter

 


Consensus Statement | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis.

30 Aug, 2022 | 12:10h | UTC

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement – European Heart Journal

 

Commentary on Twitter

 


USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.

24 Aug, 2022 | 14:21h | UTC

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement – JAMA

Editorials:

Statins for Primary Cardiovascular Disease Prevention: Time to Curb Our Enthusiasm – JAMA Internal Medicine

Statins and Primary Atherosclerotic Cardiovascular Disease Prevention—What We Know, Where We Need to Go, and Why Are We Not There Already? – JAMA Network Open

Evidence Report: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Author Interview: USPSTF Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults – JAMA

Patient Page: Statins for the Prevention of Cardiovascular Disease – JAMA

Commentary: Latest statins guidance keeps more conservative approach to preventing first stroke or heart attack – CNN

 


Position Paper | Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients.

16 Aug, 2022 | 13:42h | UTC

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP) – Journal of Sarcopenia, Cachexia and Muscle

 


Clinical Practice Update | The detection, evaluation, and management of dyslipidemia in children and adolescents.

15 Aug, 2022 | 12:12h | UTC

The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update – Canadian Journal of Cardiology

 


Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function.

12 Aug, 2022 | 15:11h | UTC

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function – Journal of the American College of Cardiology

Commentaries:

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution – TCTMD

Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies – American College of Cardiology

 


Stay Updated in Your Specialty

No spam, just news.